Background: Second and third-generation ALK inhibitors (ALKIs) have been recently approved for ALK-translocated lung cancer treatment, improving - and expanding - the first-line scenario.
Methods: In this systematic review and metanalysis, we investigated the efficacy and safety of next-generation ALKIs in untreated advanced ALK-translocated lung cancer patients, searching for randomized phase III controlled trials through databases (PubMed, EMBASE, and the Cochrane Library). Inclusion and exclusion of studies, quality assessment, data extraction, and synthesis were independently accomplished by two reviewers, with discrepancies adjudicated by a third reviewer. Stata (StataCorp., v.16) software was used for the metanalysis.
Results: In total, seven randomized controlled trials met our inclusion criteria. Comparing the results of next-generation ALKIs and control therapy (crizotinib or chemotherapy), next-generation ALKIs significantly improved progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), any lesion (aCNSRR) and measurable lesions of central nervous system response rate (mCNSRR). Safety results were similar between the experimental and control groups.
Conclusion: Our analysis confirmed that next-generation ALKIs are the preferred first-line treatment option for ALK-translocated lung cancer. They are superior to crizotinib or chemotherapy in several clinical endpoints, including OS, PFS, ORR and CNS disease control, without increased toxicity. In the absence of head-to-head data, the choice between these molecules should be guided by physician experience and preference, drug-specific safety profile and schedule.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239548 | PMC |
| http://dx.doi.org/10.3389/fonc.2022.921854 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN - ALK fusion.
Eur J Cancer
December 2024
Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy. Electronic address:
Background: Anaplastic Lymphoma Kinase (ALK) rearrangement is a rare alteration in differentiated thyroid carcinomas (DTCs). Due to its low prevalence, a few evidence are available about the use of ALK inhibitors in advanced DTCs.
Methods: We report the case of a striatin (STRN) - ALK translocated advanced thyroid carcinoma.
Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinoma.
Oncologist
July 2024
Institute for Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, 89081 Ulm, Germany.
Article Synopsis
- A case is reported involving a patient with advanced non-small cell lung adenocarcinoma who has been on crizotinib therapy and developed a new missense mutation in the ALK gene associated with resistance to this treatment.
- The EML4/ALK translocation remained detectable despite the patient's cancer recurrence, and a 3D analysis suggested that the mutation contributes to crizotinib resistance while showing potential sensitivity to other drugs like brigatinib and lorlatinib.
- The study emphasizes the effectiveness of combining preclinical and clinical approaches, including targeted sequencing and in vitro validation, which could enhance the use of molecular tumor boards in improving individualized cancer treatment strategies.
ALK Inhibitor and Chemotherapy Combinations in Models of ALK-Translocated NSCLC.
Anticancer Res
July 2024
Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland;
Background/aim: Randomized trials have shown the benefit of combining tyrosine kinase inhibitors (TKI) and chemotherapy in the treatment of epidermal growth factor receptor-mutant non-small-cell lung cancer (NSCLC). For anaplastic lymphoma kinase-rearranged (ALK) NSCLC, prospective trial results of the combination are not available and have not even been thoroughly investigated in vitro. In this study, we investigated combinations of TKI and chemotherapy using in vitro models of ALK NSCLC.
View Article and Find Full Text PDFAnaplastic lymphoma kinase-positive pulmonary inflammatory myofibroblastic tumour: a case report.
J Med Case Rep
April 2024
Lung Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK.
Background: Pulmonary inflammatory myofibroblastic tumour (IMT) is a rare condition that usually presents in young individuals and is associated with anaplastic lymphoma kinase (ALK)-translocation.
Case Presentation: We report a case of an 18-year-old Caucasian man with ALK-translocated pulmonary IMT treated with multimodality therapy. The patient presented with breathlessness and was found to have a collapsed left lung.
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Target Oncol
November 2023
Service d'Oncologie Thoracique, CHU de Rouen, Rouen, France.
Background: Although ALK-translocated (ALK+) advanced non-small cell lung cancers (aNSCLCs) are currently treated with second- or third-generation ALK inhibitors (ALK-TKIs), some patients respond durably to the first-generation ALK-TKI crizotinib.
Objective: This study aimed to describe the clinical characteristics of these long-term responders.
Patients And Methods: This national, multicenter, retrospective, non-interventional study included patients with ALK+ aNSCLCs and long-term responses to first (L1)- or subsequent (≥ L2)-line crizotinib, defined, respectively, as treatments lasting > 18 and > 10 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!